ProKidney - Class A opened lower at $1.12, compared with its previous close of $1.13. In the last trading session, the stock traded between $1.08 and $1.18. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in ProKidney - Class A is now worth
$ 13.27
Resulting in a loss of
$ 86.73 (86.73%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
50%
Hold
25%
Sell
25%
Markets Today
Today's Change
+$0.02 (+1.33%)
Day High
$1.18
Day Low
$1.08
Day Open
$1.12
Prev Close
$1.13
Volume
10,13,359
1W Return
1.78%
1M Return
-32.05%
3M Return
-29.10%
6M Return
-35.31%
1Y Return
-59.11%
Fundamentals
Market Cap ($ Mn)
239
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-47.16%
EPS (TTM)
$-0.14
Investment Returns
1 Week
1.78%
1 Month
-32.05%
3 Months
-29.10%
6 Months
-35.31%
9 Months
-42.75%
Financials
Quarterly
All values in $ Mn
0.2
Mar 25
0.2
Jun 25
0.2
Sep 25
0.2
Dec 25
0.2
Mar 26
0.1
Jun 26
Updates
2Oct
ProKidney to present eight abstracts at ASN Kidney Week 2026
ProKidney Corp. will present eight abstracts at ASN Kidney Week 2026 in Denver from October 21-25, 2026. Seven abstracts focus on translational models and drug characterization for rilparencel. One clinical abstract presents pooled Phase 2 analysis showing kidney function stabilization in advanced CKD patients. Oral presentation on graft-adjacent remodeling response scheduled for October 23, 2026.
ProKidney Corp. delivered Q2 2026 results featuring a widened net loss of $46.4 million and increased R&D spend of $36.1 million. Key operational news includes the completion of enrollment for the PROACT 1 accelerated approval subset and the appointment of Kenneth Locke as CTO.
